A series of seven clinical cases, presented to the Japanese Pediatric Association in the early 1960s, initiated the medical classification of what is now recognized as a leading cause of acquired heart disease in children worldwide. The physician who documented these symptoms, Tomisaku Kawasaki, faced significant professional skepticism before the condition gained global scientific acceptance.
Early Education and Career
Born in 1925 in the Asakusa district of Tokyo, Kawasaki was the youngest of seven children. While initially interested in the natural sciences, he pursued medicine at Chiba University, graduating in 1948. Following his internship in Chiba, he chose to specialize in pediatrics. Due to financial constraints, he began working at the Japan Red Cross Medical Center in Hiroo, Tokyo, a position he maintained for over four decades.
Twenty questions, eight minutes on the clock, and a percentile measured against everyone who has taken it. No sign-up.
Take the IQ test →The Discovery of MCLS
In 1961, Kawasaki encountered a four-year-old boy presenting with a unique collection of clinical symptoms. After documenting a second patient with identical features in 1962, he compiled a series of seven cases for the Japanese Pediatric Association. His initial submission faced rejection from peers who doubted the existence of a new disease entity. After reaching 50 documented cases, his 44-page report was published in the Japanese Journal of Allergy in 1967. The work was noted for its detailed hand-drawn illustrations of patient rashes.
Global Recognition
By 1970, a Ministry of Health and Welfare committee confirmed that the condition, which he termed mucocutaneous lymph node syndrome, was a distinct disease affecting the body's arteries. A link to cardiac complications was established in 1973. In 1974, the Kawasaki Disease Research Committee published its findings in the journal Pediatrics, marking the first time the research reached an international audience. The disease was subsequently included in Nelson’s Textbook of Pediatrics in 1992.
Legacy and Retirement
Kawasaki retired from clinical practice in 1990. He subsequently established the Japan Kawasaki Disease Research Center, serving as its director until 2019 and as honorary chairman until his death. Over the course of his career, he received numerous accolades, including the 1986 Bering Kitasato Award, the 1989 Asahi Prize, and the 1991 Japan Academy Prize. He died in Tokyo in 2020 at the age of 95.
Fast facts
- Born: 1925, Tokyo
- Died: 2020, Tokyo
- Medical Training: Chiba University
- Career Length: Over 40 years at Japan Red Cross Medical Center
- Major Recognition: Asahi Prize (1989)
- Condition Identified: Mucocutaneous lymph node syndrome
- Established: Japan Kawasaki Disease Research Center (1990)
Questions readers ask
Did Tomisaku Kawasaki like the name given to the disease?
No, he never personally referred to the condition by his own name, though he did concede that his original term was too long.
What was the main outcome of his clinical research?
His work identified a systemic condition that significantly impacts coronary arteries in children, leading to standardized diagnostic and treatment approaches.
Achievements
- Asahi Prize — 1989
- Fields: medicine and pediatrics
